Baird analyst David Rescott raised the firm’s price target on Medtronic (MDT) to $91 from $90 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and said the MedSurg miss clouds an improving return to stability.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic’s Strong Growth and Positive Outlook Reinforce Buy Rating Despite Challenges
- Medtronic Q3 Fiscal 2025 Financial Overview
- Medtronic’s Earnings Call Highlights Consistent Growth
- Medtronic’s Strong Profitability and Growth Prospects Earn Buy Rating from Analyst
- Mixed Indicators Lead to Hold Rating for Medtronic: A Balanced Outlook on Future Prospects